Form 4: Medpace CEO sells 20,794 shares via limit orders

CEO August J. Troendle sold 20,794 Medpace shares at weighted averages of $595.26 and $591 within price ranges of $590.00–$600.51 and $590.00–$593.185, and now holds 893,368 direct shares plus 4,733,019 indirectly.

Summary

• August J. Troendle (CEO, Director, 10% owner) sold 14,747 shares on 2025-11-14 at a weighted average price of $595.26, with individual trades ranging from $590.00 to $600.51.
• He sold an additional 6,047 shares on 2025-11-17 at a weighted average price of $591, with individual trades ranging from $590.00 to $593.185.
• Total shares sold: 20,794 across two trading days.
• Direct holdings after the transactions: 893,368 shares.
• Indirect beneficial ownership reported: 4,733,019 shares held by Medpace Investors, LLC ("MPI"); Troendle is the sole manager and controlling unit holder with sole voting and investment control. He disclaims beneficial ownership of MPI’s holdings except to the extent of his pecuniary interest.
• Transactions were effected pursuant to a limit order placed during an open window period.
• Weighted average prices reflect multiple trades; the reporting person will provide detailed pricing upon request.
• Form signed by Attorney-in-Fact Stephen P. Ewald on 2025-11-18.

Sentiment

Score: 5

Explanation: Neutral: routine insider selling by the CEO/10% owner with substantial remaining ownership and transparent execution details.

Positives

• Executive retains a substantial direct ownership position of 893,368 shares after the sales.
• Also reports indirect beneficial ownership of 4,733,019 shares via Medpace Investors, LLC, over which he has sole voting and investment control (while disclaiming beneficial ownership except to the extent of his pecuniary interest).
• Sales were executed via limit order during an open window period, indicating adherence to company trading policies.
• Commitment to transparency by offering full trade-by-trade pricing details upon request.

Negatives

• Insider selling by the CEO and 10% owner totaling 20,794 shares across 2025-11-14 and 2025-11-17.
• Transactions are not described as being conducted under a Rule 10b5-1(c) trading plan.

Future Outlook

No forward-looking statements or guidance are provided.

Management Comments

• Transactions were carried out via a limit order placed during an open window period.
• Reported prices are weighted averages; the shares were sold in multiple transactions within specified ranges, and detailed pricing will be provided upon request.
• As sole manager and controlling unit holder of Medpace Investors, LLC, the reporting person has sole voting and investment control over MPI’s holdings and disclaims beneficial ownership except to the extent of his pecuniary interest.

Industry Context

Insider transactions of this type are common across large contract research organizations and broader healthcare services sectors; they often reflect personal portfolio management rather than operational changes. The activity does not include operational or financial performance data.

Comparison to Industry Standards

• Magnitude and structure of sales (open-window, limit orders) are consistent with typical founder/CEO liquidity events seen at large-cap healthcare services and CRO peers.
• Retention of a large residual stake (893,368 direct shares plus significant indirect holdings via an affiliated LLC) aligns with ongoing shareholder alignment commonly observed among founder-led peers.
• No 10b5-1(c) plan is referenced; both open-window and 10b5-1 plans are customary across peers such as IQVIA and ICON, so this approach is within normal market practice.
• No financial or operating metrics are disclosed, limiting comparability to industry benchmarks (e.g., revenue growth, backlog, or margin performance).

Stakeholder Impact

• Shareholders may scrutinize insider selling, but the executive remains a significant holder.
• No changes to control or governance are indicated.
• No direct operational, customer, supplier, or employee impacts are disclosed.

Key Dates

Keywords

Medpace, MEDP, Form 4, insider sale, August J. Troendle, CEO, beneficial ownership, Medpace Investors, LLC, limit order, open window period, weighted average price